CLLS
Price
$1.44
Change
-$0.12 (-7.69%)
Updated
Sep 23 closing price
Capitalization
160.61M
46 days until earnings call
Intraday BUY SELL Signals
SLN
Price
$11.51
Change
-$0.78 (-6.35%)
Updated
Sep 23 closing price
Capitalization
1.03B
54 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CLLS vs SLN

CLLS vs SLN Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CLLS vs. SLN commentary
Sep 24, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLLS is a Hold and SLN is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
CLLS vs SLN: Fundamental Ratings
CLLS
SLN
OUTLOOK RATING
1..100
5181
VALUATION
overvalued / fair valued / undervalued
1..100
34
Fair valued
76
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
9535
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLLS's Valuation (34) in the Biotechnology industry is somewhat better than the same rating for SLN (76) in the null industry. This means that CLLS’s stock grew somewhat faster than SLN’s over the last 12 months.

CLLS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SLN (100) in the null industry. This means that CLLS’s stock grew similarly to SLN’s over the last 12 months.

CLLS's SMR Rating (98) in the Biotechnology industry is in the same range as SLN (98) in the null industry. This means that CLLS’s stock grew similarly to SLN’s over the last 12 months.

SLN's Price Growth Rating (35) in the null industry is somewhat better than the same rating for CLLS (95) in the Biotechnology industry. This means that SLN’s stock grew somewhat faster than CLLS’s over the last 12 months.

SLN's P/E Growth Rating (100) in the null industry is in the same range as CLLS (100) in the Biotechnology industry. This means that SLN’s stock grew similarly to CLLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLLSSLN
RSI
ODDS (%)
Bullish Trend 2 days ago
81%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
89%
Advances
ODDS (%)
Bullish Trend 6 days ago
79%
Bullish Trend 2 days ago
90%
Declines
ODDS (%)
Bearish Trend 8 days ago
89%
Bearish Trend 13 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 3 days ago
87%
COMPARISON
Comparison
Sep 24, 2026
Stock price -- (CLLS: $1.56 vs. SLN: $11.51)
Brand notoriety: CLLS and SLN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLLS: 75% vs. SLN: 61%
Market capitalization -- CLLS: $160.61M vs. SLN: $1.03B
CLLS [@Biotechnology] is valued at $160.61M. SLN’s [@Biotechnology] market capitalization is $1.03B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.53B. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLLS’s FA Score shows that 0 FA rating(s) are green while SLN’s FA Score has 0 green FA rating(s).

  • CLLS’s FA Score: 0 green, 5 red.
  • SLN’s FA Score: 0 green, 5 red.
According to our system of comparison, both CLLS and SLN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLLS’s TA Score shows that 5 TA indicator(s) are bullish while SLN’s TA Score has 3 bullish TA indicator(s).

  • CLLS’s TA Score: 5 bullish, 5 bearish.
  • SLN’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, CLLS is a better buy in the short-term than SLN.

Price Growth

CLLS (@Biotechnology) experienced а -3.11% price change this week, while SLN (@Biotechnology) price change was -7.92% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.63%. For the same industry, the average monthly price growth was -7.31%, and the average quarterly price growth was +9.20%.

Reported Earning Dates

CLLS is expected to report earnings on Nov 09, 2026.

SLN is expected to report earnings on Nov 17, 2026.

Industries' Descriptions

@Biotechnology (+1.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
CLLS
Daily Signal:
Gain/Loss:
SLN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HNCJX23.630.10
+0.42%
Hartford International Growth I
RIDCX27.43-0.01
-0.04%
American Funds Income Fd of Amer R-3
JWWCX129.78-0.11
-0.08%
Janus Henderson Global Research C
BISMX28.01-0.07
-0.25%
Brandes International Small Cap Equity I
PFSAX24.13-0.48
-1.95%
PGIM Jennison Financial Services A

CLLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLLS has been loosely correlated with SLN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CLLS jumps, then SLN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLLS
1D Price
Change %
CLLS100%
+3.31%
SLN - CLLS
43%
Loosely correlated
+0.33%
MDGL - CLLS
40%
Loosely correlated
-0.60%
PMVP - CLLS
38%
Loosely correlated
+2.37%
AXON - CLLS
36%
Loosely correlated
+1.61%
TGTX - CLLS
36%
Loosely correlated
+1.66%
More